Literature DB >> 9556169

Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?

H Fahrer1, M J Sauvain, E Zhioua, C Van Hoecke, L E Gern.   

Abstract

In 1986, a 26% seroprevalence of IgG- anti-Borrelia burgdorferi antibodies was observed among 950 orienteers and the incidence of new clinical infections was 0.8%. In 1993, a total of 305 seropositive orienteers were reexamined. During that time, 15 cases (4.9%) of definite/probable Lyme disease occurred in this seropositive group (12 skin manifestations and 3 monoarticular joint manifestations). Among the 12 definite cases, 9 showed new clinical infections (7 EM, 1 acrodermatitis chronica atrophicans, 1 arthritis), and 3 were recurrent (2 EM, 1 arthritis). The annual incidence (0.8%) in this seropositive group was identical to the incidence observed among the whole population in 1986. The individual antibody titer decreased slightly but the seroreversion rate was low (7%). Serology was not very helpful in identifying clinical cases and evolutions, and it can be stated, that a positive serology is much more frequent in this risk group than clinical disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9556169     DOI: 10.1023/a:1007404620701

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  18 in total

1.  Two-year survey of the incidence of Lyme borreliosis and tick-borne encephalitis in a high-risk population in Sweden.

Authors:  R Gustafson; B Svenungsson; M Forsgren; A Gardulf; M Granström
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

2.  Lyme arthritis in The Netherlands: a nationwide survey among rheumatologists.

Authors:  I Blaauw; L Nohlmans; E van den Berg-Loonen; J Rasker; S van der Linden
Journal:  J Rheumatol       Date:  1991-12       Impact factor: 4.666

3.  The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk.

Authors:  H Fahrer; S M van der Linden; M J Sauvain; L Gern; E Zhioua; A Aeschlimann
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

4.  Lyme disease: prevalence and clinical importance of Borrelia burgdorferi specific IgG in forestry workers.

Authors:  E C Guy; D E Bateman; C N Martyn; J E Heckels; N F Lawton
Journal:  Lancet       Date:  1989-03-04       Impact factor: 79.321

5.  Prevalence of antibodies to Borrelia burgdorferi in forestry workers and blood donors from the same region in Switzerland.

Authors:  D Nadal; W Wunderli; H Briner; K Hansen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-11       Impact factor: 3.267

6.  Enzyme-linked immunosorbent assay and indirect immunofluorescence assay for Lyme disease.

Authors:  H Russell; J S Sampson; G P Schmid; H W Wilkinson; B Plikaytis
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

7.  Erythema chronicum migrans disease in the Federal Republic of Germany.

Authors:  R Schmidt; J Kabatzki; S Hartung; R Ackermann
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

8.  Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities.

Authors:  A C Steere; S E Malawista; D R Snydman; R E Shope; W A Andiman; M R Ross; F M Steele
Journal:  Arthritis Rheum       Date:  1977 Jan-Feb

9.  Antibodies against Borrelia burgdorferi in Bavarian forest workers.

Authors:  P Münchhoff; B Wilske; V Preac-Mursic; G Schierz
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

10.  Lyme arthritis--a common manifestation in a highly endemic area in Sweden.

Authors:  J Berglund; B U Hansen; R Eitrem
Journal:  J Rheumatol       Date:  1995-04       Impact factor: 4.666

View more
  9 in total

Review 1.  Occupational risk of Lyme disease: an epidemiological review.

Authors:  J D Piacentino; B S Schwartz
Journal:  Occup Environ Med       Date:  2002-02       Impact factor: 4.402

Review 2.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

3.  Risk of Borrelia burgdorferi infection in western Switzerland following a tick bite.

Authors:  I Nahimana; L Gern; D S Blanc; G Praz; P Francioli; O Péter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-24       Impact factor: 3.267

4.  Use of Mass-Participation Outdoor Events to Assess Human Exposure to Tickborne Pathogens.

Authors:  Jessica L Hall; Kathrin Alpers; Kevin J Bown; Stephen J Martin; Richard J Birtles
Journal:  Emerg Infect Dis       Date:  2017-03       Impact factor: 6.883

Review 5.  Immunoserological Diagnosis of Human Borrelioses: Current Knowledge and Perspectives.

Authors:  Emilie Talagrand-Reboul; Alice Raffetin; Pierre Zachary; Benoît Jaulhac; Carole Eldin
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

6.  Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.

Authors:  Sebastian Rauer; Stephan Kastenbauer; Heidelore Hofmann; Volker Fingerle; Hans-Iko Huppertz; Klaus-Peter Hunfeld; Andreas Krause; Bernhard Ruf; Rick Dersch
Journal:  Ger Med Sci       Date:  2020-02-27

7.  Commentary: Tick talk: A glimpse into the literature.

Authors:  Parthopratim Dutta Majumder
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

8.  Evaluation of factors influencing tick bites and tick-borne infections: a longitudinal study.

Authors:  Bo Bødker Jensen; Mie Topholm Bruun; Per Moestrup Jensen; Andreas Kristian Pedersen; Pierre-Edouard Fournier; Sigurdur Skarphedinsson; Ming Chen
Journal:  Parasit Vectors       Date:  2021-05-29       Impact factor: 3.876

9.  Are Orienteers Protected Enough against Tick Bites? Estimating Human Exposure to Tick Bites through a Participative Science Survey during an Orienteering Competition.

Authors:  Jonas Durand; Laure Bournez; Julien Marchand; Claire Schmid; Irene Carravieri; Béatrice Palin; Cyril Galley; Vincent Godard; Annick Brun-Jacob; Jean-François Cosson; Pascale Frey-Klett
Journal:  Int J Environ Res Public Health       Date:  2021-03-18       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.